Anika Therapeutics ( NASDAQ: ANIK ) entered into a cooperation agreement with Caligan Partners LP. As part of the agreement, Joseph Capper, CEO of MIMEDX, and William Jellison, former CFO of Stryker, have been appointed to the company’s Board of Directors, effective immediately. In addition, the Anika Board of Directors has authorized a $40M share repurchase program, $15M of which will be effected through a 10b5-1 plan to be completed by June 30, 2025, and the remainder of which will be purchased in the open market through June 30, 2026.
This new buyback authorization replaces the company’s share repurchase program announced in April 2023. The Anika Board will temporarily expand to ten directors until the retirement of current Anika director Jeffery Thompson is effective at the 2024 Annual Meeting of Stockholders. Under the terms of the cooperation agreement, Caligan has agreed to support the Board’s full slate of directors at the 2024 Annual Meeting.
Source: Press Release More on Anika Therapeutics Anika Therapeutics, Inc. (ANIK) Q1 2024 Earnings Call Transcript Anika Therapeutics, Inc. 2024 Q1 - Results - Earnings Call Presentation Anika Therapeutics, Inc.
(ANIK) Q4 2023 Earnings Call Transcript Anika Therapeutics Q1 2024 Earnings Preview Anika Therapeutics Non-GAAP EPS of $0.05 beats by $0.28, revenue of $42.
97M beats by $1.57M.
